Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: A cost-effectiveness analysis

Pharmacotherapy

Volumn 31, Issue 6, 2011, Pages 552-565

  Perez, Alexandra ^a   Touchette, Daniel R ^b   DiDomenico, Robert J ^b   Stamos, Thomas D ^b   Walton, Surrey M ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Atrial fibrillation; Decision analysis; Heart failure; Markov model; Pharmacoeconomics; Rate control; Rhythm control

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DILTIAZEM; METOPROLOL; METOPROLOL TARTRATE; VERAPAMIL;

ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVERSION; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSE REDUCTION; HEALTH CARE COST; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE CONTROL; HEART RHYTHM CONTROL; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; SYSTEMATIC REVIEW;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEART FAILURE; HEART RATE; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79957605012     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.6.552     Document Type: Article

References (40)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009;119:480-6.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines. J Am Coll Cardiol 2006;48:854-906.
3. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9. (Pubitemid 41505035)
4. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation 2003;107:2920-5. (Pubitemid 36736633)
5. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009;54:1280-9.
6. Wyse DG, Waldo AL, DiMarco JP, et al, for the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
7. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40. (Pubitemid 35417774)
8. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6. (Pubitemid 36584236)
9. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest 2004;126:476-86. (Pubitemid 39093433)
10. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1-19.
11. Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study. Eur Heart J 2004;25:1542-9. (Pubitemid 39165633)
12. Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004;141:653-61. (Pubitemid 39440011)
13. Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999;130:625-36. (Pubitemid 29196196)
14. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998;158:1669-77. (Pubitemid 28371191)
15. Al-Khatib SM, Shaw LK, Lee KL, O'Connor C, Califf RM. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? Am J Cardiol 2004;94:797-800.
16. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the rate control versus electrical cardioversion (RACE) study. Am Heart J 2005;149:1106-11. (Pubitemid 40848157)
17. Roy D, Talajic M, Nattel S, et al, for the Atrial Fibrillation and Congestive Heat Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77. (Pubitemid 351860859)
18. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: CAFE-II study. Heart 2009;95:924-30.
19. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
20. Touchette DR, Hartung D. Markov modeling. In: Grauer DW, Lee J, Odom TD, et al, eds. Pharmacoeconomics and outcomes: applications for patient care, 2nd ed. Kansas City: American College of Clinical Pharmacy, 2003:206-30.
21. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38. (Pubitemid 24013155)
22. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409. (Pubitemid 28140699)
23. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994;14:52-8. (Pubitemid 24032682)
24. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: panel on cost-effectiveness in health and medicine. JAMA 1996;276:1339-41. (Pubitemid 26346934)
25. Centers for Disease Control and Prevention. Abridged life table. Available from http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf. Accessed June 1, 2009.
26. The Atrial Fibrillation and Congestive Heart Failure Investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the atrial fibrillation and congestive heart failure (AFCHF) trial. Am Heart J 2002;144:597-607.
27. Roy D, Talajic M, Dorian P, et al, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-20.
28. Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8. (Pubitemid 38452597)
29. Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP). Available from http://hcupnet.ahrq.gov/HCUPnet.jsp? Id=0D7AE842178B078B&Form=SelDB&JS=Y&Action=%3E%3ENext%3E%3E&-DB= NIS06. Accessed May 21, 2010.
30. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006;47:2513-20. (Pubitemid 43866357)
31. Thomson Healthcare. Red book: pharmacy's fundamental reference, 113th ed. Montevale, NJ: Thomson Reuters, 2009.
32. Walmart.com. Retail prescription program drug list. Available from http://i.walmartimages.com/i/if/hmp/fusion/customer-list.pdf. Accessed May 20, 2010.
33. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20. (Pubitemid 44050845)
34. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49. (Pubitemid 40993769)
35. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500. (Pubitemid 30398806)
36. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-73.
37. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
38. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
39. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87. (Pubitemid 351860860)
40. Talajic M, Khairy P, Levesque S, et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 2010;55:1796-802.